269 related articles for article (PubMed ID: 15523074)
1. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.
Roberts TG; Goulart BH; Squitieri L; Stallings SC; Halpern EF; Chabner BA; Gazelle GS; Finkelstein SN; Clark JW
JAMA; 2004 Nov; 292(17):2130-40. PubMed ID: 15523074
[TBL] [Abstract][Full Text] [Related]
2. Risks and benefits of phase 1 oncology trials, 1991 through 2002.
Horstmann E; McCabe MS; Grochow L; Yamamoto S; Rubinstein L; Budd T; Shoemaker D; Emanuel EJ; Grady C
N Engl J Med; 2005 Mar; 352(9):895-904. PubMed ID: 15745980
[TBL] [Abstract][Full Text] [Related]
3. Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials.
Chihara D; Lin R; Flowers CR; Finnigan SR; Cordes LM; Fukuda Y; Huang EP; Rubinstein LV; Nastoupil LJ; Ivy SP; Doroshow JH; Takebe N
Lancet; 2022 Aug; 400(10351):512-521. PubMed ID: 35964611
[TBL] [Abstract][Full Text] [Related]
4. Risks and benefits associated with novel phase 1 oncology trial designs.
Koyfman SA; Agrawal M; Garrett-Mayer E; Krohmal B; Wolf E; Emanuel EJ; Gross CP
Cancer; 2007 Sep; 110(5):1115-24. PubMed ID: 17628485
[TBL] [Abstract][Full Text] [Related]
5. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
6. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
7. Phase I therapy trials in children with cancer.
Shah S; Weitman S; Langevin AM; Bernstein M; Furman W; Pratt C
J Pediatr Hematol Oncol; 1998; 20(5):431-8. PubMed ID: 9787315
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.
Kesselheim AS; Myers JA; Avorn J
JAMA; 2011 Jun; 305(22):2320-6. PubMed ID: 21642684
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
10. Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center.
Smith TL; Lee JJ; Kantarjian HM; Legha SS; Raber MN
J Clin Oncol; 1996 Jan; 14(1):287-95. PubMed ID: 8558210
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER.
Subbiah IM; Wheler JJ; Hess KR; Hong DS; Naing A; Fu S; Kurzrock R; Tsimberidou AM
Int J Cancer; 2017 Jan; 140(1):208-215. PubMed ID: 27599876
[TBL] [Abstract][Full Text] [Related]
12. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
13. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
14. Inhaled corticosteroids in children with persistent asthma: effects on growth.
Zhang L; Prietsch SO; Ducharme FM
Evid Based Child Health; 2014 Dec; 9(4):829-930. PubMed ID: 25504972
[TBL] [Abstract][Full Text] [Related]
15. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
[TBL] [Abstract][Full Text] [Related]
16. Italian cancer figures, report 2012: Cancer in children and adolescents.
; ;
Epidemiol Prev; 2013; 37(1 Suppl 1):1-225. PubMed ID: 23585445
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials.
Gupta S; Hunsberger S; Boerner SA; Rubinstein L; Royds R; Ivy P; LoRusso P
J Natl Cancer Inst; 2012 Dec; 104(24):1860-6. PubMed ID: 23169991
[TBL] [Abstract][Full Text] [Related]
18. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
[TBL] [Abstract][Full Text] [Related]
19. Presentation and subsequent publication rates of phase I oncology clinical trials.
Camacho LH; Bacik J; Cheung A; Spriggs DR
Cancer; 2005 Oct; 104(7):1497-504. PubMed ID: 16116590
[TBL] [Abstract][Full Text] [Related]
20. Improving the quality of abstract reporting for phase I cancer trials.
Strevel EL; Chau NG; Pond GR; Murgo AJ; Ivy PS; Siu LL
Clin Cancer Res; 2008 Mar; 14(6):1782-7. PubMed ID: 18347180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
